SCHEMBL1735846

SCHEMBL1735846

CCCCCC(CC)C(CCCCCCCCCCCCCCCCO)C(=O)OC(=O)CCCCCCCCCCCCCCCCCO

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.42
LMNA P02545 4/20 0.42
KDM4E B2RXH2 1/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 1/20 0.42
PRKCA P17252 3/20 0.40
PRKCE Q02156 1/20 0.40
PRKCQ Q04759 1/20 0.40
PRKCD Q05655 1/20 0.40
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
ATM Q13315 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PAM P19021 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33770 0.88 DGKA (0.50) DGKALMNAKDM4EDUSP3MEN1
SCHEMBL14830029 0.86 DGKA (0.44) DGKALMNAMAPTTSHRALDH1A1
SCHEMBL14830615 0.85 MAPT (0.41) DGKALMNAMAPTTSHRALDH1A1
SCHEMBL2119253 0.83 MGLL (0.49) DGKALMNAKDM4EDUSP3MAPT
Palmitic Acid SCHEMBL8518708 0.83 FFAR4 (0.53) DGKAMEN1KMT2AMAPTTSHR
SCHEMBL11747177 0.80 LMNA (0.42) LMNAMEN1KMT2ATSHRALDH1A1
SCHEMBL29109107 0.80 DGKA (0.47) DGKALMNAKDM4EDUSP3MEN1
SCHEMBL31065847 0.80 LMNA (0.50) DGKALMNAKDM4EDUSP3MEN1
SCHEMBL29277359 0.79 LMNA (0.51) DGKALMNAKDM4EDUSP3MEN1
SCHEMBL29128054 0.79 LMNA (0.51) DGKALMNAKDM4EDUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190321329-A1 FORMULATION FOR THE TREATMENT OF ACNE AKZO NOBEL CHEMICALS INT BV (NL) 2019-10-24 US disclosed
EP-3340975-B1 FORMULATION FOR THE TREATMENT OF ACNE AKZO NOBEL CHEMICALS INT BV (NL) 2019-07-24 EP disclosed
US-10278945-B2 Formulation for the treatment of acne AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2019-05-07 US disclosed
US-20190022050-A1 FORMULATION FOR THE TREATMENT OF ACNE NOURYON CHEMICALS INTERNATIONAL B.V. (NL) 2019-01-24 US disclosed
EP-3340975-A1 FORMULATION FOR THE TREATMENT OF ACNE Akzo Nobel Chemicals International B.V. (NL) 2018-07-04 EP disclosed
US-20170156999-A1 PERSONAL CARE COMPOSITION IN A DISSOLVABLE CONTAINER Henkel IP & Holding GmbH (DE) 2017-06-08 US disclosed
WO-2017036897-A1 FORMULATION FOR THE TREATMENT OF ACNE AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) 2017-03-09 WO disclosed
WO-2016110872-A1 FOOT CARE COMPOSITIONS Zydus Wellness Limited (IN) 2016-07-14 WO disclosed
US-9072675-B2 Non-irritating benzoyl peroxide ESSENTIAL INGREDIENTS, INC. (US) 2015-07-07 US disclosed
US-20140161853-A1 Non-Irritating Benzoyl Peroxide ESSENTIAL INGREDIENTS, INC. (US) 2014-06-12 US disclosed
US-8697130-B1 Non-irritating benzoyl peroxide ESSENTIAL INGREDIENTS, INC. (US) 2014-04-15 US disclosed
EP-2172185-B1 Cosmetic material comprising octyl hydroxy stearate oligomer PARAHERMOSA CO LTD (JP) 2011-11-23 EP disclosed
US-20100111884-A1 UV ABSORBER FORMULATIONS CIBA CORPORATION (US) 2010-05-06 US disclosed
US-20090196894-A1 Self Tanning Composition CIBA CORP. 2009-08-06 US disclosed
EP-2026746-A2 SELF TANNING COMPOSITION Ciba Holding Inc. (CH) 2009-02-25 EP disclosed
WO-2007137958-A2 SELF TANNING COMPOSITION CIBA HOLDING INC. (CH) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111884-A1 UV ABSORBER FORMULATIONS C1R, C1S, C9 DGKA 4376/4885LMNA 1485/4885KDM4E 1391/4885
US-20090196894-A1 Self Tanning Composition C9, KRT18, F12 DGKA 2047/4885LMNA 657/4885KDM4E 373/4885
US-20190321329-A1 FORMULATION FOR THE TREATMENT OF ACNE ACOX1, HSD17B12, ACOX3 DGKA 2278/4885LMNA 4226/4885KDM4E 3881/4885
US-20190022050-A1 FORMULATION FOR THE TREATMENT OF ACNE ACOX1, HSD17B12, ACOX3 DGKA 2278/4885LMNA 4226/4885KDM4E 3881/4885
US-10278945-B2 Formulation for the treatment of acne ACOX1, HSD17B12, ACOX3 DGKA 2278/4885LMNA 4226/4885KDM4E 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.